TRPharm has started a €40 Million investment for the construction of the 15.000 sq. meter state-of-the-art biopharmaceutical facility for production of monoclonal antibodies. TRPharm broke ground in June 2016 for its green field project in Çerkezköy industrial area which will conform the highest standards as per local and international regulatory requirements.
TRPharm’s facility will be outfitted with state-of-the-art technology for all the equipment and systems. The facility will have multi-product capabilities starting with Bio-API manufacturing utilizing a variety of upstream and downstream processes. In addition, it will carryout fill and finish to produce high-quality innovative products including biosimilars and novel products.
SUPPORT FROM AUTHORITIES
The facility project has been accepted into the Strategic Incentive Scheme by Turkish authorities, qualifying the project as an unprecedented contribution to the technological know-how of the country. Hence, the project and products that will be produced in the facility receive wide spread support from all branches.